AT
Antigenix Therapeutics, Inc.
SEC filingOther Health Care · Princeton, NJ
Amount raised$3.4Msold at filing
Total offering$8.4M$5M still open
Investors in the raise17count reported to the SEC
FiledOct 24, 2025first sale Oct 22, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Kwesi Frimpong-BoatengDirector
Christopher WhitfieldExecutive Officer, Director
Shaun HawkinsDirector
Executive officers, directors and promoters as listed on the Form D.